Exploring CAR T-Cell Therapy During the COVID-19 Pandemic: Mitigation and Management of Adverse Events

Article

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor T cells. Join us Tuesday, May 26, 2020 at 8 PM EST.

Date/Time: Tuesday, May 26, 2020 at 8 PM EST

This OncLive® webinar series will focus on the continued impact of the COVID-19 pandemic on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T cells. We will feature a panel of leading experts to discuss important topics and considerations surrounding CAR T-cell therapies and the patient populations impacted during this time.

Click here to register today!

Topics:

  • Review of data on adverse events and strategies for management
  • The CAR T cell experience and vein-to-vein time
  • Real-world experience using bridging therapy in the setting of new drug approvals and pending approvals

Faculty:

Loretta J. Nastoupil, MD, Associate Professor; Section Chief, Indolent Lymphoma; Section Chef, New Drug Development, Department Lymphoma/Myeloma, UT MD Anderson Cancer Center

Ahmed Galal, MD, FRACP, MSc, Professor of Medicine, Medicine, Hematologic Malignancies and Cellular Therapy, Duke School of Medicine

Matthew Lunning, DO, Associate Professor, Internal Medicine; Medical Director, Lymphoma Research, Division of Oncology & Hematology, University of Nebraska Medical Center

Sponsored By:

Related Videos
Deepak L. Bhatt, MD, MPH, MBA
John A. Charlson, MD
Jeffrey Chamberlain, PhD
David Porter, MD
Judy Lieberman, MD, PhD, the endowed chair in cellular and molecular medicine at Boston Children’s Hospital
Jonathan W. Weinsaft, MD
Omid Hamid, MD
Atul Malhotra, MD, PhD, the head of the early neurodevelopment clinic at Monash Children's Hospital
Robert J. Hopkin, MD
Michael Kelly, PhD
Related Content
© 2024 MJH Life Sciences

All rights reserved.